The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression
Open accessAbstract
The mechanisms by which administration of interferon-α induces neuropsychiatric side effects, such as depressive symptoms and changes in cognitive function, are not clear as yet. Direct influence on serotonergic neurotransmission may contribute to these side effects. In addition, the enzyme indoleamine 2,3-dioxygenase (IDO), which converts tryptophan into kynurenine, may play an important role, first, because IDO activation leads to reduced levels of tryptophan, the precursor of serotonin (5-HT), and thus to reduced central 5-HT synthesis. Second, kynurenine metabolites such as 3-hydroxy-kynurenine (3-OH-KYN) and quinolinic acid (QUIN) have toxic effects on brain function. 3-OH-KYN is able to produce oxidative stress by increasing the production of reactive oxygen species (ROS), and QUIN may produce overstimulation of hippocampal N-methyl-d-aspartate (NMDA) receptors, which leads to apoptosis and hippocampal atrophy. Both ROS overproduction and hippocampal atrophy caused by NMDA overstimulation have been associated with depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
Lipid peroxidation and antioxidants as biomarkers of tissue damage
Gutteridge, J. M. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.12.1819 · Cited by 1,844
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Sheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382 · cited 1×
“Major depression is associated with hippocampal volume loss.(78,79) Hypothalamic-pituitary-adrenal (HPA) axis inhibition appears to be mediated by negative feedback from circulating glucocorticoids.”
BackgroundQuinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060
Evidence for an immune response in major depression: A review and hypothesis
Maes, M. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)00101-m · Cited by 1,003
Self-citationRole of 5-HT in stress, anxiety, and depression
Graeff, F. G., Guimarães, F. S., De Andrade, T. G. C. S., & Deakin, J. F. W. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02135-3 · Cited by 984
Sickness behavior as a new target for drug development
Kent, S., Bluthé, R.-M., Kelley, K. W., & Dantzer, R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90012-u · Cited by 863
Perkins, M. N., & Stone, T. W. (1982) · Brain Research · doi:10.1016/0006-8993(82)91048-4 · Cited by 849
Research works printed but not linked: 5
- Qin ZH, 1996, Brain Res, 725, 166
- Heyes MP, 1998, FASEB J, 12, 881
- Sanni LA, 1998, Am J Pathol, 152, 611
- Mangoni A, 1974, Adv Biochem Psychopharmacol, 11, 293
- Maes M, 1995, Psychopharmacology, 933
Cited by
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235
Self-citationKorte, S. M., Koolhaas, J. M., Wingfield, J. C., & McEwen, B. S. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.08.009 · Cited by 1,097
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
Self-citationLeonard, B., & Maes, M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.12.005 · Cited by 805
Self-citationMaes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Self-citationRedox regulation of the immune response
Morris, G., Gevezova, M., Sarafian, V., & Maes, M. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00902-0 · Cited by 575
Self-citationGlucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554
Maes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.014 · Cited by 544
Self-citationThe Microbiota–Gut–Brain Axis in Psychiatric Disorders
Góralczyk-Bińkowska, A., Szmajda-Krygier, D., & Kozłowska, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911245 · Cited by 495
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Cytokines as mediators of depression: what can we learn from animal studies?
Dunn, A. J., Swiergiel, A. H., & Beaurepaire, R. D. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.023 · Cited by 459
Frenois, F., Moreau, M., O’Connor, J., Lawson, M., Micon, C., Lestage, J., Kelley, K. W., Dantzer, R., & Castanon, N. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.03.005 · Cited by 438
“…brain microglia, leading to a decrease of the bioavailability of tryptophan for serotonin synthesis (Capuron et al., 2002b; Capuron & Dantzer, 2003; Wichers & Maes, 2004) and the generation of potentially neurotoxic tryptophan metabolites such as 3- hydroxykynurenine and quinolinic acid (Stone,…”
BackgroundRheumatoid arthritis and depression: an inflammatory perspective
Nerurkar, L., Siebert, S., McInnes, I. B., & Cavanagh, J. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30255-4 · Cited by 413
The kynurenine system and immunoregulation
Mándi, Y., & Vécsei, L. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0681-y · Cited by 401
Serotonergic vulnerability and depression: assumptions, experimental evidence and implications
Jans, L. A. W., Riedel, W. J., Markus, C. R., & Blokland, A. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001920 · Cited by 374
Trisomy 21 consistently activates the interferon response
Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., et al. (2016) · eLife · doi:10.7554/elife.16220 · Cited by 362
ANISMAN, H., MERALI, Z., & HAYLEY, S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.004 · Cited by 337
Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan
Turner, E. H., Loftis, J. M., & Blackwell, A. D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.004 · Cited by 326
Hayley, S., Poulter, M. O., Merali, Z., & Anisman, H. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.051 · Cited by 324
Godbout, J. P., Moreau, M., Lestage, J., Chen, J., Sparkman, N. L., Connor, J. O., Castanon, N., Kelley, K. W., Dantzer, R., & Johnson, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301649 · Cited by 299
Anisman, H. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0902 · Cited by 292
“This activity, in turn, promotes degradation of the 5-HT precursor tryptophan, thereby reducing 5-HT function and increasing vulnerability to depressive illness.(10,188,196,204) In addition, indoleamine-2,3dioxygenase promotes the catabolism of tryptophan into kynurenine and then into the oxidative metabolites 3-hydro…”
Miura, H., Ozaki, N., Sawada, M., Isobe, K., Ohta, T., & Nagatsu, T. (2008) · Stress · doi:10.1080/10253890701754068 · Cited by 282
Dysregulated relationship of inflammation and oxidative stress in major depression
Rawdin, B. J., Mellon, S. H., Dhabhar, F. S., Epel, E. S., Puterman, E., Su, Y., Burke, H. M., Reus, V. I., Rosser, R., Hamilton, S. P., et al. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.11.011 · Cited by 255
“IDO upregulation results in a depletion of tryptophan and a concomitant increase in metabolites, 3-hydroxy-kynurenine and quinolonic acid, which then provoke ROS production (Maes et al., 2011d; Miller et al., 2009; Wichers and Maes, 2004).”
BackgroundBull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Depression, dementia and immune dysregulation
Hayley, S., Hakim, A. M., & Albert, P. R. (2021) · Brain · doi:10.1093/brain/awaa405 · Cited by 186
Addressing the tuberculosis–depression syndemic to end the tuberculosis epidemic
Sweetland, A. C., Kritski, A., Oquendo, M. A., Sublette, M. E., Norcini Pala, A., Silva, L. R. B., Karpati, A., Silva, E. C., Moraes, M. O., Silva, J. R. L. E., et al. (2017) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.16.0584 · Cited by 177
Inflammatory cytokine-associated depression
Lotrich, F. E. (2015) · Brain Research · doi:10.1016/j.brainres.2014.06.032 · Cited by 183
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Associations Between Bipolar Disorder and Metabolic Syndrome: A Review
Taylor, V., & MacQueen, G. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0704 · Cited by 152
Nikkheslat, N., Zunszain, P. A., Horowitz, M. A., Barbosa, I. G., Parker, J. A., Myint, A.-M., Schwarz, M. J., Tylee, A. T., Carvalho, L. A., & Pariante, C. M. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.02.002 · Cited by 147
“…suggested to induce depressive symptoms not only by directly affecting the brain but also modulating the serotonergic system (Dantzer et al., 2011; Wichers and Maes, 2004) through indoleamine-2,3-dioxygenase (IDO) enzyme overstimulation, possibly leading to tryptophan (TRP) depletion (Wichers and…”
Diet-Derived Fatty Acids, Brain Inflammation, and Mental Health
Melo, H. M., Santos, L. E., & Ferreira, S. T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00265 · Cited by 136
CD4+CD25+ Regulatory T Cell Depletion Modulates Anxiety and Depression-Like Behaviors in Mice
Kim, S.-J., Lee, H., Lee, G., Oh, S.-J., Shin, M.-K., Shim, I., & Bae, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042054 · Cited by 130
Inflammation-induced depression: Its pathophysiology and therapeutic implications
Jeon, S. W., & Kim, Y.-K. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.10.016 · Cited by 134
The role of neuroinflammation on pathogenesis of affective disorders
Rhie, S. J., Jung, E.-Y., & Shim, I. (2020) · Journal of Exercise Rehabilitation · doi:10.12965/jer.2040016.008 · Cited by 126
Emerging comorbidities in adult asthma: risks, clinical associations, and mechanisms
Kankaanranta, H., Kauppi, P., Tuomisto, L. E., & Ilmarinen, P. (2016) · Mediators of Inflammation · doi:10.1155/2016/3690628 · Cited by 122
Neuropsychiatric disorders related to interferon and interleukins treatment
Myint, A. M., Schwarz, M. J., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9114-5 · Cited by 116
Moaddel, R., Fabbri, E., Khadeer, M. A., Carlson, O. D., Gonzalez-Freire, M., Zhang, P., Semba, R. D., & Ferrucci, L. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw046 · Cited by 99
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102
Watkins, C. C., Sawa, A., & Pomper, M. G. (2014) · Translational Psychiatry · doi:10.1038/tp.2013.119 · Cited by 100
Lieb, K., Engelbrecht, M. A., Gut, O., Fiebich, B. L., Bauer, J., Janssen, G., & Schaefer, M. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.030 · Cited by 77
Liang, G., Kow, A. S. F., Yusof, R., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2024) · Biomedicines · doi:10.3390/biomedicines12010184 · Cited by 68
(2015) · Europe PMC (PubMed Central) · Cited by 58
Interferon therapy and its association with depressive disorders – A review
Lai, J. Y., Ho, J. X., Kow, A. S. F., Liang, G., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1048592 · Cited by 46
Tyagi, P., Tasleem, M., Prakash, S., & Chouhan, G. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109489 · Cited by 42
Metadata
- Authors
- Wichers, M. C., & Maes, M.
- Venue
- Journal of Psychiatry and Neuroscience
- Publisher
- Canadian Science Publishing
- Published
- 2004-01
- Volume
- 29
- Issue
- 1
- Pages
- 11-17
- ISSN
- 1180-4882 (ISSN-L)
- 1488-2434
- OpenAlex
- W4413979613
- Cited by
- 285
- References
- 84
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.nrcresearchpress.com/page/about/CorporateTextAndDataMining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.